TIA
CADL icon

Traphagen Investment Advisors’s Candel Therapeutics CADL Stock Holding History

Traphagen Investment Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,215
Closed -$27.2K – 177
2024
Q1 		$27.2K Buy
+17,215
New +$25.6K ﹤0.01% 173

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MML Investors Services
MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Traphagen Investment Advisors's CADL Position: Q2 2024 in Review

Traphagen Investment Advisors sold out of Candel Therapeutics (CADL) in Q2 2024, closing a stake of 17,215 shares — an estimated $27.2K sold.

Traphagen Investment Advisors first reported a position in CADL in Q1 2024 and held it in 1 quarter. The position peaked at $27.2K in Q1 2024. 45 funds tracked by Wall St. Rank hold CADL as of Q2 2024.

  • Traphagen Investment Advisors reported no remaining Candel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Traphagen Investment Advisors sold 17,215 Candel Therapeutics shares in Q2 2024, an estimated $27.2K.
  • Traphagen Investment Advisors first reported a position in Candel Therapeutics in Q1 2024 and held it in 1 quarter.
  • Traphagen Investment Advisors's Candel Therapeutics position peaked at $27.2K in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2024.

Based on Traphagen Investment Advisors's 13F filing for Q2 2024, filed 23 Jul 2024.